Compare SVM & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVM | TRAX |
|---|---|---|
| Founded | 2003 | 2025 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2005 | 2026 |
| Metric | SVM | TRAX |
|---|---|---|
| Price | $7.26 | $44.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $14.25 | ★ $75.17 |
| AVG Volume (30 Days) | ★ 2.6M | 545.7K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.19 | N/A |
| Revenue Next Year | $69.05 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.11 | $15.69 |
| 52 Week High | $15.77 | $54.78 |
| Indicator | SVM | TRAX |
|---|---|---|
| Relative Strength Index (RSI) | 32.11 | 50.77 |
| Support Level | N/A | $40.72 |
| Resistance Level | $10.02 | $48.94 |
| Average True Range (ATR) | 0.48 | 3.21 |
| MACD | -0.06 | -0.76 |
| Stochastic Oscillator | 2.28 | 14.42 |
Silvercorp Metals Inc is engaged in the acquisition, exploration, development, and mining of mineral properties. The Company's producing mines are located in China, and current exploration and development projects are located in China, Ecuador and Kyrgyz Republic. The company operates in single segment. The Company mainly produces and sells silver, lead, zinc, gold and other metals. The company's producing projects are Ying Mining District, GC Mine; construction projects are El Domo; permitting project is BYP Mine; development project includes Condor, Tulkubash/Kyzyltash.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.